From: Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study
Breast cancer survivors | Hazard ratio | ||||||
---|---|---|---|---|---|---|---|
Treatment modalities | Median age (years) | Cases of hypothyroidism | Numbers | Person years | IR pr. 1000 PY (95% CI) | Crude (95% CI) | Adjusted1 (95% CI) |
RT−/CT− | 66.8 | 728 | 20,754 | 181,597 | 4.01 (3.72–4.31) | Reference group | |
RT−/CT+ | 50.1 | 160 | 4042 | 40,329 | 3.97 (3.38–4.63) | 0.99 (0.83–1.17) | 1.10 (0.91–1.32) |
RTc/CT− | 62.1 | 245 | 6615 | 55,188 | 4.44 (3.90–5.03) | 1.12 (0.96–1.29) | 1.15 (0.99–1.34) |
RTc/CT+ | 51.8 | 82 | 2252 | 19,127 | 4.29 (3.41–5.32) | 1.08 (0.86–1.36) | 1.19 (0.94–1.51) |
RTn/CT− | 62.5 | 254 | 6065 | 48,237 | 5.27 (4.64–5.95) | 1.32 (1.14–1.53) | 1.36 (1.17–1.58) |
RTn/CT+ | 50.1 | 243 | 4846 | 39,922 | 6.09 (5.35–6.90) | 1.53 (1.32–1.77) | 1.71 (1.45–2.01) |